Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide ... but some have experienced more serious reactions, such as pancreatitis," she told Fox News ...

Meanwhile, 6.1% of those taking Zepbound stopped the trial because of adverse reactions, compared to 8 ... considering the current market leaders like Zepbound and Wegovy are administered via ...

Although Novo was first to market with Wegovy and its sister drug Ozempic for diabetes, Lilly has gained the lead in obesity prescriptions with Zepbound. The US company’s diabetes version of the ...

Zepbound’s performance in this direct comparison strengthens Lilly’s position in the rapidly growing weight loss medication market. The drug operates as a dual GIP and GLP-1 receptor agonist ...